These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 8758918

  • 21. An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells.
    Yokozaki H, Budillon A, Tortora G, Meissner S, Beaucage SL, Miki K, Cho-Chung YS.
    Cancer Res; 1993 Feb 15; 53(4):868-72. PubMed ID: 8428367
    [Abstract] [Full Text] [Related]

  • 22. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.
    Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D.
    Nat Med; 1996 Jun 15; 2(6):668-75. PubMed ID: 8640558
    [Abstract] [Full Text] [Related]

  • 23. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo.
    Chmura SJ, Dolan ME, Cha A, Mauceri HJ, Kufe DW, Weichselbaum RR.
    Clin Cancer Res; 2000 Feb 15; 6(2):737-42. PubMed ID: 10690561
    [Abstract] [Full Text] [Related]

  • 24. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Mani S, Rudin CM, Kunkel K, Holmlund JT, Geary RS, Kindler HL, Dorr FA, Ratain MJ.
    Clin Cancer Res; 2002 Apr 15; 8(4):1042-8. PubMed ID: 11948111
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.
    Dean NM, McKay R, Condon TP, Bennett CF.
    J Biol Chem; 1994 Jun 10; 269(23):16416-24. PubMed ID: 7911467
    [Abstract] [Full Text] [Related]

  • 26. Application of secondary structure prediction in antisense drug design targeting protein kinase C-alpha mRNA and QSAR analysis.
    Song HF, Tang ZM, Yuan SJ, Zhu BZ.
    Acta Pharmacol Sin; 2000 Jan 10; 21(1):80-6. PubMed ID: 11263253
    [Abstract] [Full Text] [Related]

  • 27. Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts.
    Green DW, Roh H, Pippin JA, Drebin JA.
    J Surg Res; 2001 Nov 10; 101(1):16-20. PubMed ID: 11676549
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Modulation of apoptosis, tumorigenesity and metastatic potential with antisense H-ras oligodeoxynucleotides in a high metastatic tumor model of hepatoma: LCI-D20.
    Liao Y, Tang ZY, Ye SL, Liu KD, Sun FX, Huang Z.
    Hepatogastroenterology; 2000 Nov 10; 47(32):365-70. PubMed ID: 10791191
    [Abstract] [Full Text] [Related]

  • 30. Involvement of the alpha isoenzyme of protein kinase C in the growth inhibition induced by phorbol esters in MH1C1 hepatoma cells.
    Perletti GP, Smeraldi C, Porro D, Piccinini F.
    Biochem Biophys Res Commun; 1994 Dec 30; 205(3):1589-94. PubMed ID: 7811240
    [Abstract] [Full Text] [Related]

  • 31. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha.
    Dennis JU, Dean NM, Bennett CF, Griffith JW, Lang CM, Welch DR.
    Cancer Lett; 1998 Jun 05; 128(1):65-70. PubMed ID: 9652794
    [Abstract] [Full Text] [Related]

  • 32. Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer.
    Denham DW, Franz MG, Denham W, Zervos EE, Gower WR, Rosemurgy AS, Norman J.
    Surgery; 1998 Aug 05; 124(2):218-23; discussion 223-4. PubMed ID: 9706141
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
    Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI.
    Cancer; 2004 Jan 15; 100(2):321-6. PubMed ID: 14716767
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 39. Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modifications.
    McKay RA, Cummins LL, Graham MJ, Lesnik EA, Owens SR, Winniman M, Dean NM.
    Nucleic Acids Res; 1996 Feb 01; 24(3):411-7. PubMed ID: 8602351
    [Abstract] [Full Text] [Related]

  • 40. [Effects of inhibition of PKC alpha on breast cancer cell phenotype and expressions of cyclin E and CDK2].
    Sang JL, Wang YC.
    Shi Yan Sheng Wu Xue Bao; 1999 Dec 01; 32(4):367-71. PubMed ID: 12548864
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.